HongKong:6855

Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., July 6, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the com...

2020-07-06 13:00 349

Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors

SUZHOU, China and ROCKVILLE, Md., June 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and senescence diseases, today announced a clinical collaboration with Acerta P...

2020-06-22 07:15 364

Ascentage Pharma Submits Its First New Drug Application to National Medical Products Administration, for HQP1351, the First Third-Generation BCR-ABL Inhibitor in China

SUZHOU, China and ROCKVILLE, Md., June 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that Guangzhou Healthquest P...

2020-06-18 17:30 406

Ascentage Pharma Announces First Patient Dosed in the Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for the Treatment of Patients with Chronic Hepatitis B

SUZHOU, China, and ROCKVILLE, MD., June 17, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase II clinical ...

2020-06-17 13:20 341

(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies

SUZHOU, China and ROCKVILLE, Md., May 31, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company presented fo...

2020-05-31 20:00 1276

Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia

SUZHOU, China, and ROCKVILLE, Md., May 4, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Adm...

2020-05-04 18:30 541

Ascentage Pharma Releases 2019 Annual Results, Reports Increased Investment in R&D and Advances in Global Clinical Development

SUZHOU, China and ROCKVILLE, MD, March 29, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for the...

2020-03-30 08:00 889

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-24 12:30 3067

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-24 12:24 3116

Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 in the United States

SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/I...

2020-03-23 19:00 1022

Ascentage Pharma Announces Clearances for Three Phase Ib/II Clinical Studies of APG-2575 in China and the U.S., Beginning Simultaneous Clinical Development in Three Hematologic Malignancy Indications

SUZHOU, China and ROCKVILLE, MD., March 9, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that two clinical studies of...

2020-03-09 20:00 505

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China

SUZHOU, China and ROCKVILLE, MD., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has receive...

2020-02-24 22:00 1214

Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"

SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results ...

2019-12-11 08:00 9904

Ascentage Pharma Breaks Ground on its Global Headquarters, R&D Center and Manufacturing Facility in the Suzhou Industrial Park

SUZHOU, China and ROCKVILLE, Md., Nov. 20, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies, announced that the groundbreaking ceremony for the Company's global headquarters, R&D center, and manufacturi...

2019-11-21 11:30 750